Zollinger‑Ellison syndrome (gastric acid hypersecretion) - Causes, Treatment & When to See a Doctor

```html

What is Zollinger‑Ellison syndrome (gastric acid hypersecretion)?

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑secreting tumors (called gastrinomas) develop in the pancreas or duodenum. These tumors produce excessive amounts of the hormone gastrin, which in turn stimulates the stomach lining to release large volumes of gastric acid. The resulting “gastric acid hypersecretion” can damage the lining of the stomach and duodenum, cause recurrent peptic ulcers, and lead to a variety of digestive complaints.

Although ZES accounts for less than 1 % of all peptic‑ulcer disease, it is clinically important because the ulcers are often refractory to standard therapy and because the underlying tumors have malignant potential. Early recognition and treatment can prevent complications such as severe bleeding, perforation, and metastatic cancer.

Sources: Mayo Clinic; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); WHO.

Common Causes

Most cases of ZES are caused by sporadic gastrinomas, but several conditions increase the risk or are associated with similar gastric‑acid hypersecretion. Below are 8–10 recognized contributors:

• Gastrinomas (sporadic) – neuroendocrine tumors arising in the duodenum (≈70 %) or pancreas.
• Multiple Endocrine Neoplasia type 1 (MEN‑1) – an inherited syndrome that predisposes to gastrinomas, parathyroid, and pituitary tumors.
• Multiple Endocrine Neoplasia type 4 (MEN‑4) – rarer genetic disorder also linked to gastrin‑producing tumors.
• Familial Isolated Gastrinoma (FIG) – hereditary gastrinoma without other MEN features.
• Chronic H. pylori infection – can cause secondary hypergastrinemia and, in rare cases, promote tumorigenesis.
• Autoimmune chronic atrophic gastritis – loss of parietal cells leads to compensatory gastrin rise, although true gastrinomas are uncommon.
• Long‑term proton‑pump inhibitor (PPI) use – suppresses stomach acid, leading to feedback‑driven gastrin elevation; may unmask underlying gastrinomas.
• Chromogranin‑A secreting neuroendocrine tumors – a broader class of neuroendocrine tumors that can produce gastrin.
• Secondary hypergastrinemia from renal failure – reduced clearance of gastrin can mimic ZES but usually without a tumor.

Associated Symptoms

Because excessive gastric acid attacks the mucosa throughout the upper gastrointestinal (GI) tract, patients with ZES often experience a constellation of symptoms:

• Recurrent or persistent peptic ulcers (especially multiple, distal, or difficult‑to‑heal ulcers)
• Epigastric burning pain that may improve with meals (ulcer‑related) or worsen after eating (acidic load)
• Diarrhea or watery stools – the high acid load inactivates pancreatic enzymes and damages the intestinal lining.
• Steatorrhea (fatty stools) – malabsorption due to enzyme inactivation.
• Unexplained weight loss despite adequate intake.
• Frequent heartburn or gastro‑esophageal reflux disease (GERD) symptoms.
• Occasional nausea/vomiting especially after large meals.
• Signs of anemia (fatigue, pallor) from chronic GI bleeding.

When ZES is part of MEN‑1, patients may also have symptoms of hyperparathyroidism (bone pain, kidney stones) or pituitary adenomas (headaches, visual changes).

When to See a Doctor

Because the ulcers in ZES often behave atypically, prompt medical evaluation is essential if you notice any of the following:

• Recurrent ulcer pain despite taking proton‑pump inhibitors (PPIs) for ≥ 8 weeks.
• Multiple ulcers discovered on endoscopy, especially if they are located beyond the duodenum.
• Unexplained, chronic diarrhea (> 3 loose stools per day) or fatty stools.
• Sudden, significant weight loss without a change in diet.
• Persistent heartburn or GERD symptoms that do not improve with standard therapy.
• Family history of MEN‑1 or known gastric neuroendocrine tumors.

Early referral to a gastroenterologist or endocrinologist can lead to targeted testing and treatment, reducing the risk of complications.

Diagnosis

Diagnosing ZES involves confirming hypergastrinemia, establishing that high gastrin is driving acid overproduction, and locating the gastrinoma.

Laboratory Tests

• Fasting serum gastrin level – a level > 1,000 pg/mL is highly suggestive; levels > 150 pg/mL with a gastric pH < 2 strongly support ZES.
• Secretin stimulation test – paradoxical rise in gastrin after IV secretin (≥ 120 pg/mL increase) is diagnostic.
• Serum chromogranin A – often elevated in neuroendocrine tumors; useful for monitoring.
• Basic metabolic panel and renal function – to rule out secondary hypergastrinemia from kidney disease.

Imaging Studies

• Endoscopic ultrasound (EUS) – high‑resolution visualization of small pancreatic/duodenal lesions.
• Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT – detects gastrinomas that express somatostatin receptors.
• Multiphasic contrast‑enhanced CT or MRI of the abdomen – helps locate primary tumors and assess for metastases (especially liver).
• Upper endoscopy (EGD) – identifies ulcer location, severity, and may obtain biopsies to exclude malignancy.

Additional Assessments

• Genetic testing for MEN‑1 or MEN‑4 mutations when there is a suggestive family history.
• Bone density scan if hyperparathyroidism is suspected.

Treatment Options

Therapy aims to control acid production, eradicate or control the gastrinoma, and monitor for recurrence or metastasis.

Medical Management

• High‑dose proton‑pump inhibitors (PPIs) – the cornerstone for acid control (e.g., omeprazole 60 mg daily or equivalent). PPIs are usually required long‑term.
• Histamine‑2 receptor antagonists – may be added for breakthrough symptoms.
• Somatostatin analogues (octreotide or lanreotide) – bind somatostatin receptors on gastrinomas, decreasing gastrin release and sometimes shrinking tumors.
• For patients with MEN‑1‑associated ZES, calcimimetics (cinacalcet) may help control hyperparathyroidism and indirectly reduce gastrin levels.

Surgical Options

• Localized tumor resection – enucleation or pancreaticoduodenectomy when the tumor is confined and resectable.
• Debulking surgery – for metastatic disease; reduces tumor burden and gastrin output.
• Liver-directed therapies (radiofrequency ablation, hepatic artery embolization) for liver metastases.

Targeted and Systemic Therapies

• Peptide receptor radionuclide therapy (PRRT) using ^177Lu‑DOTATATE for somatostatin‑receptor positive tumors.
• Cytotoxic chemotherapy (e.g., streptozocin‑based regimens) – reserved for aggressive or refractory disease.

Home and Lifestyle Measures

• Take PPIs exactly as prescribed, usually 30 minutes before breakfast.
• Avoid foods that exacerbate acid reflux (spicy, fatty, citrus, caffeine, alcohol).
• Small, frequent meals may reduce post‑prandial acid spikes.
• Maintain adequate hydration; electrolyte loss from chronic diarrhea can be mitigated with oral rehydration solutions.
• Stop smoking – nicotine stimulates gastric acid secretion.

Prevention Tips

Because most gastrinomas arise sporadically, primary prevention is limited. However, certain strategies can reduce risk or catch disease early:

• Screen at‑risk families – individuals with a known MEN‑1 or MEN‑4 mutation should undergo regular gastrin level checks and imaging.
• Prompt treatment of Helicobacter pylori infection to avoid chronic gastritis that may increase gastrin secretion.
• Use PPIs judiciously; unnecessary long‑term use can raise gastrin levels and potentially mask underlying gastrinomas.
• Adopt a balanced diet low in irritants and maintain a healthy weight to lower baseline ulcer risk.

Emergency Warning Signs

Understanding Zollinger‑Ellison syndrome and its hallmark gastric‑acid hypersecretion empowers patients to recognize early signs, seek timely care, and adhere to treatment that can dramatically improve quality of life.

References: Mayo Clinic. “Zollinger‑Ellison syndrome.”; NIDDK. “Gastrinomas and ZES.”; WHO Classification of Tumours of the Digestive System, 5th Ed.; American Journal of Gastroenterology, 2022; Cleveland Clinic. “Neuroendocrine Tumors of the Pancreas.” ```